{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:58:51Z","timestamp":1793314731161,"version":"4.5.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamaoncol.2019.0684","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:36:33Z","timestamp":1558611393000},"page":"993","source":"Crossref","is-referenced-by-count":287,"title":["Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Thomas B.","family":"Karasic","sequence":"first","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"O\u2019Hara","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Loaiza-Bonilla","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"},{"name":"now at Cancer Treatment Centers of America, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Reiss","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursina R.","family":"Teitelbaum","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut","family":"Borazanci","sequence":"additional","affiliation":[{"name":"Virginia G. Piper Cancer Center, HonorHealth, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"De Jesus-Acosta","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, The Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Redlinger","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Burrell","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Laheru","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, The Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[{"name":"Virginia G. Piper Cancer Center, HonorHealth, Phoenix, Arizona"},{"name":"Translational Genomic Research Institute, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi K.","family":"Amaravadi","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Drebin","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"},{"name":"now at Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"coi190020r1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma.","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"coi190020r2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"coi190020r3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"coi190020r4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer.","volume":"17","author":"Levy","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"coi190020r5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1172\/JCI28833","article-title":"Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.","volume":"117","author":"Amaravadi","year":"2007","journal-title":"J Clin Invest"},{"issue":"7565","key":"coi190020r6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature14587","article-title":"Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.","volume":"524","author":"Perera","year":"2015","journal-title":"Nature"},{"issue":"8","key":"coi190020r7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/2159-8290.CD-14-0362","article-title":"Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.","volume":"4","author":"Yang","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"coi190020r8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1101\/gad.2016111","article-title":"Pancreatic cancers require autophagy for tumor growth.","volume":"25","author":"Yang","year":"2011","journal-title":"Genes Dev"},{"key":"coi190020r9","doi-asserted-by":"publisher","first-page":"e15213","DOI":"10.1200\/jco.2015.33.15_suppl.e15213","article-title":"Phase 1 trial of gemcitabine\/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.","volume":"33","author":"O\u2019Hara","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi190020r10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"34","key":"coi190020r12","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial.","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"coi190020r13","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1200\/JCO.2017.35.15_suppl.3545","article-title":"Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.","volume":"35","author":"O'Hara","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi190020r14","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1245\/s10434-017-5880-9","article-title":"Inhibition of autophagy improves pathologic and biomarker response to preoperative gemcitabine\/nab-paclitaxel in potentially resectable pancreatic cancer: a phase II randomized controlled trial.","volume":"24","author":"Miller-Ocuin","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"coi190020r15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-018-4584-2","article-title":"Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps.","volume":"18","author":"Boone","year":"2018","journal-title":"BMC Cancer"},{"issue":"7479","key":"coi190020r16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nature12865","article-title":"p53 status determines the role of autophagy in pancreatic tumour development.","volume":"504","author":"Rosenfeldt","year":"2013","journal-title":"Nature"},{"issue":"4","key":"coi190020r17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.celrep.2014.03.061","article-title":"Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression.","volume":"7","author":"Kinsey","year":"2014","journal-title":"Cell Rep"},{"issue":"3","key":"coi190020r18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2159-8290.CD-17-0952","article-title":"Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms.","volume":"8","author":"Yang","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"coi190020r19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jgo","article-title":"A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.","volume":"9","author":"Windon","year":"2018","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"coi190020r20","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-11-0269","article-title":"Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.","volume":"10","author":"Kim","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"coi190020r11","unstructured":"US Dept of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Published May 28, 2009. Accessed April 22, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/7\/993\/17712473\/jamaoncology_karasic_2019_oi_190020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:01:22Z","timestamp":1562842882000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2019.0684"}},"subtitle":["A Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.0684","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}